+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Hematologic Malignancies Testing Market by Product (Consumables, Services, Testing Kits), Technology (Fluorescence In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing), Disease Type, End-Users - Forecast 2024-2030- Product Image
Global Hematologic Malignancies Testing Market by Product (Consumables, Services, Testing Kits), Technology (Fluorescence In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing), Disease Type, End-Users - Forecast 2024-2030- Product Image
Sale

Global Hematologic Malignancies Testing Market by Product (Consumables, Services, Testing Kits), Technology (Fluorescence In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing), Disease Type, End-Users - Forecast 2024-2030

  • PDF Icon

    Report

  • 184 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5924675
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Hematologic Malignancies Testing Market size was estimated at USD 3.35 billion in 2023, USD 3.60 billion in 2024, and is expected to grow at a CAGR of 7.82% to reach USD 5.69 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hematologic Malignancies Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hematologic Malignancies Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hematologic Malignancies Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, Inc., Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., HORIBA, Ltd., ICON PLC, Illumina, Inc., Invitae Corporation, Invivoscribe, Inc., Laboratory Corporation of America Holdings, Leica Biosystems Nussloch GmbH, Myriad Genetics, Inc., Natera, Inc., Nikon Instruments, Ortho Clinical Diagnostics, PerkinElmer Corporation, QIAGEN N.V., Siemens AG, Sysmex Corporation, and Sysmex Inostics Inc.

Market Segmentation & Coverage

This research report categorizes the Hematologic Malignancies Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Consumables
    • Services
    • Testing Kits
  • Technology
    • Fluorescence In Situ Hybridization
    • Immunohistochemistry
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Disease Type
    • Leukemia
    • Lymphoma
    • Multiple Myeloma
    • Myelodysplastic Syndrome
    • Myeloproliferative Neoplasms
  • End-Users
    • Hospitals
    • Research Institutions
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Hematologic Malignancies Testing Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hematologic Malignancies Testing Market?
  3. What are the technology trends and regulatory frameworks in the Hematologic Malignancies Testing Market?
  4. What is the market share of the leading vendors in the Hematologic Malignancies Testing Market?
  5. Which modes and strategic moves are suitable for entering the Hematologic Malignancies Testing Market?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Hematologic Malignancies Testing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising aging population and incidences of hematologic malignancies
5.1.1.2. Inclination toward early diagnosis and treatment
5.1.1.3. Adoption of immunotherapies and targeted drugs
5.1.2. Restraints
5.1.2.1. High cost of hematologic malignancy treatment
5.1.3. Opportunities
5.1.3.1. Emphasis on personalized medicine approaches
5.1.3.2. Increasing number of clinical trials globally
5.1.4. Challenges
5.1.4.1. Adverse effects associated with hematologic malignancies
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Hematologic Malignancies Testing Market, by Product
6.1. Introduction
6.2. Consumables
6.3. Services
6.4. Testing Kits
7. Hematologic Malignancies Testing Market, by Technology
7.1. Introduction
7.2. Fluorescence In Situ Hybridization
7.3. Immunohistochemistry
7.4. Next-Generation Sequencing
7.5. Polymerase Chain Reaction
8. Hematologic Malignancies Testing Market, by Disease Type
8.1. Introduction
8.2. Leukemia
8.3. Lymphoma
8.4. Multiple Myeloma
8.5. Myelodysplastic Syndrome
8.6. Myeloproliferative Neoplasms
9. Hematologic Malignancies Testing Market, by End-Users
9.1. Introduction
9.2. Hospitals
9.3. Research Institutions
9.4. Specialty Clinics
10. Americas Hematologic Malignancies Testing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Hematologic Malignancies Testing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Hematologic Malignancies Testing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Adaptive Biotechnologies
14.1.3. Agilent Technologies, Inc.
14.1.4. Beckman Coulter, Inc.
14.1.5. Becton, Dickinson and Company
14.1.6. Bio-Rad Laboratories, Inc.
14.1.7. F. Hoffmann-La Roche Ltd.
14.1.8. HORIBA, Ltd.
14.1.9. ICON PLC
14.1.10. Illumina, Inc.
14.1.11. Invitae Corporation
14.1.12. Invivoscribe, Inc.
14.1.13. Laboratory Corporation of America Holdings
14.1.14. Leica Biosystems Nussloch GmbH
14.1.15. Myriad Genetics, Inc.
14.1.16. Natera, Inc.
14.1.17. Nikon Instruments
14.1.18. Ortho Clinical Diagnostics
14.1.19. PerkinElmer Corporation
14.1.20. QIAGEN N.V.
14.1.21. Siemens AG
14.1.22. Sysmex Corporation
14.1.23. Sysmex Inostics Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET RESEARCH PROCESS
FIGURE 2. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2023 VS 2030
FIGURE 3. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. HEMATOLOGIC MALIGNANCIES TESTING MARKET DYNAMICS
FIGURE 7. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 10. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 12. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 14. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 10. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 15. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 21. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 37. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 38. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 39. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 40. CANADA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 41. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 42. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 43. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 44. MEXICO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 59. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 60. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 61. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 62. CHINA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 63. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 64. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 66. INDIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 71. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 72. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 73. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 74. JAPAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 95. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 96. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 97. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 98. THAILAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 108. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 109. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 111. DENMARK HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 112. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 113. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 114. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 115. EGYPT HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 116. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 117. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 119. FINLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 120. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 121. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 123. FRANCE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 124. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 125. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 127. GERMANY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 132. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 133. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 134. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 135. ITALY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 144. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 145. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 147. NORWAY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 148. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 149. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 150. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 151. POLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 152. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 153. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 154. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 155. QATAR HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 168. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 169. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 170. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 171. SPAIN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 180. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 181. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 182. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 183. TURKEY HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 192. HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 193. HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2023
TABLE 194. HEMATOLOGIC MALIGNANCIES TESTING MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • HORIBA, Ltd.
  • ICON PLC
  • Illumina, Inc.
  • Invitae Corporation
  • Invivoscribe, Inc.
  • Laboratory Corporation of America Holdings
  • Leica Biosystems Nussloch GmbH
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Nikon Instruments
  • Ortho Clinical Diagnostics
  • PerkinElmer Corporation
  • QIAGEN N.V.
  • Siemens AG
  • Sysmex Corporation
  • Sysmex Inostics Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 3.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.69 Billion
Compound Annual Growth Rate7.8%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Hematologic Malignancies Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 - Product Image

Hematologic Malignancies Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027

  • Report
  • 114 Pages
  • Global
From
Global CAR T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumors), End-Use (Cancer Treatment Centers, Hospitals) - Forecast 2024-2030 - Product Image

Global CAR T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumors), End-Use (Cancer Treatment Centers, Hospitals) - Forecast 2024-2030

  • Report
  • 195 Pages
  • Global
From
Global T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Forecast 2024-2030 - Product Image

Global T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Forecast 2024-2030

  • Report
  • 185 Pages
  • Global
From
Hematologic Malignancies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 - Product Image

Hematologic Malignancies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • Report
  • 148 Pages
  • Global
From
T Cell Therapy Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type [CAR T-cell Therapy and T-cell Receptor-based], Indication, and Geography - Product Image

T Cell Therapy Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type [CAR T-cell Therapy and T-cell Receptor-based], Indication, and Geography

  • Report
  • 138 Pages
  • Global
From

About the Hematologic Malignancies Testing Market

The Hematologic Malignancies Testing market is a subset of the Diagnostics industry, focusing on the detection and diagnosis of blood-related cancers. Tests are used to detect the presence of cancerous cells in the blood, bone marrow, and lymph nodes. These tests can also be used to monitor the progression of the disease and to determine the best course of treatment. Common tests include flow cytometry, immunophenotyping, and cytogenetic analysis. The Hematologic Malignancies Testing market is highly competitive, with a range of companies offering tests and services. These include Abbott Laboratories, Becton Dickinson, Bio-Rad Laboratories, Danaher Corporation, and Roche Diagnostics. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.